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Abstract The 90 kDa heat shock protein, Hsp90, is a main
functional component of an important cytoplasmic chaperone
complex, and it is involved in various cellular processes, such
as cell proliferation, di¡erentiation and apoptosis. Identi¢cation
of Hsp90 as a molecular target of various anticancer drugs
highlighted its importance from the clinical point of view.
Here we summarize the current knowledge on various Hsp90
isoforms regarding their genomic location, molecular evolution,
functional di¡erences, di¡erential induction after various envi-
ronmental stresses and in pathological conditions as well as the
growing importance of discriminating between Hsp90 isoforms
in clinical practice.
% 2004 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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1. Introduction: Hsp90, an abundant chaperone
The 90 kDa heat shock protein, Hsp90, is one of the most
abundant proteins in eukaryotic cells, comprising 1^2% of
cellular proteins under non-stress conditions. Its contribution
to various cellular processes including signal transduction,
protein folding, protein degradation and morphological evo-
lution has been extensively studied [1^5]. The full functional
activity of Hsp90 is gained in concert with other co-chaper-
ones, playing an important role in the folding of newly syn-
thesized proteins and stabilization and refolding of denatured
proteins after stress. Apart from its co-chaperones, Hsp90
binds to an array of client proteins, where the co-chaperone
requirement varies and depends on the actual client. There is a
growing list of Hsp90 client proteins, now including several
hundred proteins. Interestingly, most of the clients include
molecules involved in signal transduction [5].
2. Hsp90 genes and isoforms
There are two major cytoplasmic isoforms of Hsp90,
Hsp90K (inducible form/major form) and Hsp90L (constitu-
tive form/minor form) [1]. A recent report added another iso-
form to the Hsp90 family, Hsp90N, which is associated with
cellular transformation [6]. Additional Hsp90 analogues in-
clude Grp94 in the endoplasmic reticulum and Hsp75/
TRAP1 in the mitochondrial matrix [1]. Hsp75 possesses a
unique LxCxE motif [7], which is absent in all other Hsp90
family members, and depends on stress kinases for its tran-
scriptional activation [8]. We have mapped hsp90K and hsp90L
to the human genome, and our search identi¢ed cDNA se-
quences in chromosomes 1, 3, 4, 11 and 14 for hsp90K and in
chromosomes 4, 6, 10, 13, 14 and 15 for hsp90L showing
several novel copies in the genome and raising the possibility
of several pseudogenes of human hsp90. The genomic loca-
tions of human hsp90K at 14q32^33, hsp90L at 6p21 and hsp75
at 16p13.3 are recognized as functional (http://www.infobio-
gen.fr [9,10]). Mammalian hsp90 genes, in contrast to most
eukaryotic hsp genes, are composed of several introns and
exons (Fig. 1) [1]. The nucleotide sequences of hsp90K and
hsp90L have much less similarity compared to the sequences
of their protein products, particularly in their 5P and 3P non-
coding regions, the introns, and the regulatory 5P £anking
sequences [11,12]. In contrast, the hsp90N gene shares a
high similarity with that of hsp90K [6]. Hsp90 isoforms have
¢ve highly conserved regions, called ‘signature sequences’, of
which three are in the N-terminal domain (Fig. 2; amino acids
38^59, 106^114, 130^145 of human Hsp90K) and two in the
middle domain (amino acids 360^370 and 387^401) [12].
3. Molecular evolution of Hsp90 isoforms
Studies on the phylogenetic distribution of hsp90 have con-
centrated on the cytoplasmic isoforms [12,13]. The mamma-
lian hsp90 isoforms K and L arose by gene duplication roughly
500 million years ago [12]. There is a relatively high conser-
vation within these isoforms, and it was proposed that not
only mammalian Hsp90 acquired a novel chaperone activity,
but the K and L isoforms may also display di¡erent chaperone
activities [14]. Available data suggest that the endoplasmic
reticulum hsp90 homologue originated via a paralogous gene
duplication very early in eukaryotic evolution [12]. In con-
trast, the additional hsp90 isoform hsp90N represents a very
recent gene rearrangement of hsp90K [6].
4. Biochemical di¡erences between Hsp90 isoforms
Since the biochemical separation of Hsp90 isoforms is
rather di⁄cult, most studies have been carried out with a
mixture of the K and L Hsp90 isoforms. An important di¡er-
0014-5793 / 04 / $30.00 M 2004 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.
doi:10.1016/S0014-5793(04)00229-7
*Corresponding author. Fax: (36)-1-266 7480.
E-mail address: csermely@puskin.sote.hu (P. Csermely).
1 On leave from the Centre for Cellular and Molecular Biology,
Hyderabad 500 007, India.
FEBS 28199 17-3-04 Cyaan Magenta Geel Zwart
FEBS 28199 FEBS Letters 562 (2004) 11^15
ence is that the K form readily dimerizes, whereas the L form
does so with much less e⁄ciency. Hsp90 is mainly a constitu-
tive dimer (KK or LL), however, monomers (K or L), hetero-
dimers (KL) and higher oligomers of both isoforms also exist.
The dimerization potential resides mainly at the carboxy-ter-
minal 190 amino acids of Hsp90 (Fig. 2) [1,6]. In addition,
there are certain areas in the amino acid sequences that di¡er
between the K and L isoforms raising the possibility of more
isoform-speci¢c functions, such as di¡erential binding to cli-
ent proteins. Though Hsp90N shares high sequence homology
with the other two Hsp90 isoforms, it lacks the 25 kDa N-ter-
minal domain, a highly conserved ATP binding site of Hsp90
[6]. The mitochondrial isoform Hsp75 is similar to the bacte-
rial Hsp90 homologue, Hsp75, where the highly charged hinge
region of the N-terminal section is missing [1,7].
5. Functional di¡erences between Hsp90 isoforms
As expected, the isoform speci¢city is not restricted to the
biochemical level but extends to the functional role of Hsp90
in cell di¡erentiation and development. Thus a regulatory role
of Hsp90K in muscle cell di¡erentiation of zebra¢sh has been
reported [15]. In contrast, overexpression of Hsp90K inhibited
cellular di¡erentiation of embryonal carcinoma cells to tro-
phoectoderm [16]. Reduction of Hsp90K by disruption of heat
shock factor (HSF) genes caused instability of the cyclin-de-
pendent kinase cdc2 against thermal stress [17]. Hsp90L has
been shown to play a major role in trophoblast di¡erentiation,
and Hsp90L-de¢cient homozygous mice with normal expres-
sion of Hsp90K failed to di¡erentiate to form placental laby-
rinths [18]. Hsp90L overexpression is observed throughout the
germ cell lineage from very early stages of development to
adult oocytes and spermatocytes [19]. Later studies con¢rmed
these observations in various models and di¡erent stages of
development, and suggested that Hsp90L is required for early
embryonic development [20^22]. Thus, there are multiple dif-
ferences between Hsp90 isoforms in cell di¡erentiation and
embryonic development in various organisms.
There is both in vivo and in vitro evidence that Hsp90 ^
along with other Hsps ^ directly binds to tubulin and actin,
the major components of the eukaryotic cytoskeleton [1]. Iso-
form-speci¢c cytoskeletal interactions have been reported by
Cambiazo et al. [23] suggesting that Hsp90L is the major
microtubule-interacting protein, compared to Hsp90K.
Hsp90 is involved in cell survival and the various pathways
leading to cell death, such as apoptosis or necrosis [24].
Our current knowledge of Hsp90 isoforms suggests that
only the K isoform of Hsp90 is involved in nicotine-induced
apoptosis as seen by DNA fragmentation and caspase-3 acti-
vation [25].
Fig. 1. A schematic view of the intron/exon structure of human hsp90 isoforms. Data are from www.ensembl.org.
Fig. 2. Schematic representation of various Hsp90 isoforms. The numbering 1 through 900 refers to the amino acid sequence. The functional
signi¢cance of the domains and the approximate position of the speci¢c drug binding sites are listed.
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6. Di¡erences between the expression mechanisms of Hsp90
isoforms
The transcription of the hsp90K gene is tightly regulated by
the 5P upstream promoter sequences containing several heat
shock elements (HSEs), which are involved in the inducible
gene expression of hsp90K [9,26]. Quite interestingly, although
Hsp90L is not regarded as a highly inducible family member
of the 90 kDa Hsps [27], the typical HSEs in the ¢rst intron of
the human hsp90L gene play a critical role as heat shock-
dependent enhancers of transcription (Fig. 3). Initiation
from within the ¢rst intron is important for the high con-
stitutive expression as well as for the highly e⁄cient heat in-
ducibility of the hsp90L gene. HSF1 binds to a heat shock-
speci¢c enhancer composed of two typical HSEs in the ¢rst
intron of the hsp90L gene, which e⁄ciently enhances heat
shock-induced transcription initiated from 3P downstream
sequences within the intron [28]. As a unique feature com-
pared to intron-less hsp genes, both hsp90K and hsp90L regu-
late hsp90 mRNA splicing after a severe stress in Drosophila
[29]. The similarity of regulatory sequences for Hsp90
isoforms in di¡erent mammalian species is usually higher
than that of the two Hsp90 isoform genes in one animal.
For example, the 600 bp sequence in the proximal region
£anking the mouse hsp84 and that of human hsp90L gene are
V85% conserved [30], while those of the human hsp90K
[26] and hsp90L genes [31] are completely di¡erent. In addition
to the K and L isoforms of Hsp90, Hsp90N has been pro-
posed to have di¡erential promoter utilization and/or splicing
[6].
Beyond the typical HSF/HSE-activating pathway for heat
shock genes, we have recently found that the human hsp90L
gene is speci¢cally enhanced by the protein kinase CO isoform
in the heat shock response [32]. Additionally, Stat1, of the
protein family of signal transducers and activators of tran-
scription, plays a complex role in the expression of the heat
shock-sensitive version, the hsp90K gene. Phosphorylated
Stat1Tyr701 appears after heat shock and restrains the over-
expression of the hsp90K gene in Jurkat cells. The restrained
hsp90K gene expression is released with the overexpression of
a Stat1Y701F mutant or by insertion of a GAS (Q-interferon-
activated sequence) element to nucleotides 31612/31604 rel-
ative to the transcription start site of the hsp90K gene. Ectopic
wild-type Stat1 represses the heat shock-induced expression of
the hsp90K gene, but not that of its constitutive counterpart,
hsp90L (X.S. Chen, J.S. Wang, X.Y. Li, F.Y. Heng, X.K.
Cheng, N.H. Wu and Y.F. Shen, submitted for publication).
It is thus suggested that the expression levels of the two ver-
sions of human hsp90 genes may be accurately coordinated in
vivo to accommodate the requirement of individual cellular
functions in heat shock response.
7. Di¡erential induction of Hsp90 isoforms
Hsp90K expression is lower compared to Hsp90L in most
cells. hsp90K is highly inducible, and its selective induction in
nicotine-induced apoptosis was cytoprotective [25]. An unusu-
al, high expression of hsp90K was shown to be associated with
tumor progression [33], enhanced cell cycle regulation [34],
and growth factor-mediated signaling via tyrosine kinases
[35]. In contrast to hsp90K, hsp90L expression is thought to
be constitutive. However, hsp90L can also be induced. Hsp90L
is probably involved in long-term cellular adaptation. In sup-
port of this, Hsp90L expression was shown to be associated
with the development of drug resistance [36]. Due to its gen-
erally higher levels than Hsp90K, Hsp90L is the major form of
Hsp90 involved in normal cellular functions, such as mainte-
nance of the cytoarchitecture [37], di¡erentiation [38], cyto-
protection [24]. For more details of di¡erential induction/ex-
pression of hsp90 isoforms in response to various extracellular
signals and stress events see the comprehensive review by
Csermely et al. [1].
8. Hsp90 isoforms and clinical practice: isoform expression in
tumors
There are a few reports that Hsp90 expression is associated
with many types of tumors; however, Ogata et al. [39] showed
that acute and chronic pancreatic tumors have enhanced
Hsp90K expression, whereas benign tumors do not. In addi-
tion, overexpression of Hsp90K is associated with a poor
prognosis of breast cancer [40], pancreatic carcinoma [41],
and human leukemia [33]. In patients with systemic lupus
erythematosus, the disease is associated with increased
Hsp90L transcription [42]. Hsp90L expression has been shown
to be associated with chronic tumors [39]. Hsp90L expression
is implicated in multidrug resistance through its interaction
with the P-glycoprotein, a key component of the development
of multidrug resistance [36]. Though basal level expression of
Hsp90N is observed in normal rat ¢broblasts, overexpression
of this protein results in cellular transformation through aug-
menting Raf/Ras activity [6].
Fig. 3. Schematic representation of HSEs in the promoter region of human hsp90K and hsp90L genes. E1, exon 1; E2, exon 2.
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9. Hsp90 isoforms and clinical practice: inhibition of Hsp90
isoforms
Hsp90 inhibition provides a recently developed, important
pharmacological platform for anticancer therapy. With the
inhibition of this pleiotropic chaperone, many survival and
signaling pathways can be inhibited simultaneously. The inhi-
bition pattern of a geldanamycin analogue in clinical trials
shows a preference for cancer cells due to the higher-a⁄nity
binding to the cancer-speci¢c, complexed form of Hsp90 [43].
Most of the Hsp90-related antitumor drugs, like geldanamy-
cin analogues, radicicol and the purin sca¡old inhibitors, are
aimed to the N-terminal ATP binding domain (Fig. 2)
[43^47]. The nucleotide binding pocket is fairly conserved in
Hsp90K and Hsp90L, thus we cannot expect a major di¡er-
ence in the inhibition of these isoforms by the available Hsp90
inhibitors.
However, due to the lack of the N-terminal ATP domain in
Hsp90N, these drugs are ine¡ective for the inhibition of the
chaperone function of Hsp90N. Despite the missing N-termi-
nal domain this Hsp90 isoform is still a chaperone [6], which
is in agreement with the proposed chaperone activity of the
highly conserved C-terminal domain of both Hsp90 isoforms
being independent of that associated with the N-terminus [1].
Hence, it is important to design speci¢c inhibitors for both the
N-terminus and C-terminus of Hsp90. The recent ¢nding of a
C-terminal nucleotide binding site (Fig. 2) [48^50] and the
characterization of its di¡erential nucleotide binding speci¢c-
ity [51] might help to accomplish this task.
10. Conclusions and perspectives
The current understanding of Hsp90 as a molecular chap-
erone explains well its role in many cellular functions both in
normal and in pathophysiological conditions. Hsp90 chaper-
one function alone, however, has failed to rationalize the iso-
form-speci¢c function of this heat shock protein so far. In the
cellular context Hsp90K emerges as a fast-response, cytopro-
tective isoform, while Hsp90L seems to be associated with
long-term cellular adaptation and facilitated cellular evolution
(Table 1). The ¢rst report on the isoform-speci¢c variation of
Hsp90 polymorphism in humans opens a wide arena for phar-
macologists to design more speci¢c inhibitors of Hsp90 for
antitumor therapies [52]. Isoform-dependent Hsp90 polymor-
phism warns us further that the isoform speci¢city of Hsp90
functions needs much more study in the future. From this
knowledge even more focused pharmacological intervention,
like isoform-speci¢c Hsp90 inhibitors, may also be born.
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